SCHEMBL3042857

SCHEMBL3042857

COCC=COBOC=CCOC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9616140 0.73
SCHEMBL17130642 0.73
SCHEMBL9616141 0.73
SCHEMBL7814020 0.71
SCHEMBL1059082 0.71
SCHEMBL1059084 0.71
SCHEMBL17239087 0.67
SCHEMBL19418916 0.65 AKT1 (0.33)
SCHEMBL3826482 0.65
SCHEMBL6176340 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2781510-B1 HIV INHIBITING 5,6-SUBSTITUTED PYRIMIDINES JANSSEN SCIENCES IRELAND UC (IE) 2016-12-14 EP disclosed
EP-2781510-A1 HIV inhibiting 5,6-substituted pyrimidines Janssen R&D Ireland (IE) 2014-09-24 EP disclosed
EP-2114902-B1 HIV INHIBITING 5,6-SUBSTITUTED PYRIMIDINES JANSSEN R & D IRELAND (IE) 2014-09-17 EP disclosed
US-8318736-B2 HIV inhibiting 5,6-substituted pyrimidines JANSSEN R&D IRELAND (IE) 2012-11-27 US disclosed
US-20100261722-A1 HIV INHIBITING 5, 6-SUBSTITUTED PYRIMIDINES TIBOTEC PHARMACEUTICALS LTD. 2010-10-14 US disclosed
EP-2114902-A2 HIV INHIBITING 5,6-SUBSTITUTED PYRIMIDINES Tibotec Pharmaceuticals (IE) 2009-11-11 EP disclosed
WO-2008080965-A2 HIV INHIBITING 5,6-SUBSTITUTED PYRIMIDINES TIBOTEC PHARMACEUTICALS LTD. (IE) 2008-07-10 WO disclosed